UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549 

 

 

 

  FORM 8-K  

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 16, 2016

 

    FORTRESS BIOTECH, INC.

 

  (Exact Name of Registrant as Specified in Charter)    

 

Delaware 001-35366 20-5157386

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

2 Gansevoort Street, 9th Floor, New York, New York 10014
 (Address of Principal Executive Offices) (Zip Code)

 

 

Registrant’s Telephone Number, Including Area Code: (781) 652-4500  

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 5.07.Submission of Matters to a Vote of Security Holders.

 

Fortress Biotech, Inc. (the “Company”) held its 2016 annual meeting of stockholders on June 16, 2016. At the meeting, stockholders elected the following seven members to the Company’s Board of Directors to serve until the Company’s next annual meeting of stockholders or until their successors have been elected and qualified, based on the following votes:

 

Nominee   For   Against   Abstain   Broker
Non-Votes
Lindsay A. Rosenwald, M.D.   22,633,932   2,410,294   13,245   18,100,681
Eric K. Rowinsky, M.D.   23,632,126   1,411,274   14,071   18,100,681
Jimmie Harvey, Jr., M.D.   22,634,148   1,401,052   1,022,271   18,100,681
Malcolm Hoenlein   22,622,787   1,412,408   1,022,276   18,100,681
Dov Klein   22,427,413   1,607,782   1,022,276   18,100,681
J. Jay Lobell   22,425,933   1,608,262   1,023,276   18,100,681
Michael S. Weiss   22,543,662   2,499,738   14,071   18,100,681

 

At the meeting, stockholders also ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016. The vote for such ratification was 42,819,465 shares for, 284,356 shares against, 54,331 shares abstaining, and no broker non-votes.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  FORTRESS BIOTECH, INC.  
     
     
Date:  June 21, 2016 /s/ Lindsay A. Rosenwald  
  Lindsay A. Rosenwald, M.D.,  
  Chairman, President and Chief Executive Officer